Navigation Links
Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the 2013 UBS Global Healthcare Conference in New York City
Date:5/16/2013

SAN FRANCISCO, May 16, 2013 /PRNewswire/ -- Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard W. Robin , is scheduled to present at the upcoming 2013 UBS Global Healthcare Conference in New York at the Sheraton New York Hotel on Tuesday, May 21, 2013 at 10:00 a.m. Eastern time.

The presentation will be accessible via a Webcast through a link posted in the Investor Relations, Events Calendar section of the Nektar website: http://www.nektar.com. This Webcast will be available for replay until June 22, 2013.

About Nektar
Nektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its PEGylation and advanced polymer conjugation technology platforms.  Nektar has a robust R&D pipeline of potentially high-value therapeutics in oncology, pain and other therapeutic areas. In the area of pain, Nektar has an exclusive worldwide license agreement with AstraZeneca for naloxegol (NKTR-118), an investigational drug candidate, which has completed Phase 3 development as a once- daily, oral tablet for the treatment of opioid-induced constipation.  This agreement also includes NKTR-119, an earlier stage development program that is a co-formulation of naloxegol and an opioid.  NKTR-181, a novel mu-opioid analgesic candidate for chronic pain conditions, is in Phase 2 development in osteoarthritis patients with chronic knee pain.  NKTR-192, a novel mu-opioid analgesic in development to treat acute pain is in Phase 1 clinical development.  In oncology, etirinotecan pegol (NKTR-102) is being evaluated in a Phase 3 clinical study (the BEACON study) for the treatment of metastatic breast cancer and is also in Phase 2 studies for the treatment of ovarian and colorectal cancers. In anti-infectives, Amikacin Inhale is in Phase 3 studies conducted by Bayer Healthcare as an adjunctive treatment for intubated and mechanically ventilated patients with Gram-negative pneumonia.

Nektar's technology has enabled eight approved products in the U.S. or Europe through partnerships with leading biopharmaceutical companies, including UCB's Cimzia® for Crohn's disease and rheumatoid arthritis, Roche's PEGASYS® for hepatitis C and Amgen's Neulasta® for neutropenia.  Additional development-stage products that leverage Nektar's proprietary technology platform include Baxter's BAX 855, a long-acting PEGylated rFVIII program, which is in Phase 3 clinical development.

Nektar is headquartered in San Francisco, California, with additional operations in Huntsville, Alabama and Hyderabad, India.  Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com.

Contact:
Jennifer Ruddock /Nektar Therapeutics
(415) 482-5585


'/>"/>
SOURCE Nektar Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Nektar to Announce Financial Results for the First Quarter of 2012 on Wednesday, May 2, 2012, After Close of U.S.-Based Financial Markets
2. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
3. Nektar Therapeutics President and CEO Howard W. Robin to Present at the Jefferies 2012 Global Healthcare Conference in New York
4. Nektar Announces that FDA Grants Fast Track Designation to NKTR-181, a New Oral Opioid Analgesic Molecule, for the Treatment of Moderate to Severe Chronic Pain
5. Nektar Announces Start of Enrollment in Phase 2 Study of NKTR-181, a Novel Opioid Analgesic Molecule, for Treatment of Chronic Pain
6. Nektar Announces Initiation of Investigator-Sponsored Trial Evaluating Etirinotecan Pegol (NKTR-102) in Patients with Bevacizumab (Avastin)-resistant High-Grade Glioma
7. Nektar Therapeutics Reports Financial Results for the Second Quarter of 2012
8. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the UBS 2012 Global Life Sciences Conference in New York City
9. Nektar to Announce Financial Results for the Third Quarter of 2012 On Tuesday, November 13, 2012, After Close of U.S.-Based Financial Markets
10. Nektar Announces that FDA Grants Fast Track Designation to Etirinotecan Pegol (NKTR-102) for the Treatment of Metastatic Breast Cancer
11. Nektar To Host Conference Call To Discuss The Positive Phase 3 Clinical Results For Naloxegol
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2019)... Mont. (PRWEB) , ... January 15, 2019 , ... WebBuy, ... 2019 ready to partner with more dealers eager to reach a demographic of customers ... or used vehicle from a dealer’s inventory and complete the purchase on the dealer’s ...
(Date:1/15/2019)... ... January 15, 2019 , ... ... background screening, compliance and credentialing solutions, announces it was recently acquired by ... solutions. Cisive caters to the complex challenges and program needs of large ...
(Date:1/15/2019)... , ... January 15, 2019 , ... ... Double Board-Certified, Ivy League-educated and fellowship-trained Facial Plastic and Reconstructive Surgeon . ... Plastic, Reconstructive & Laser Surgery in California, Dr. Ransom serves patients with a ...
Breaking Medicine Technology:
(Date:1/20/2019)... ... January 18, 2019 , ... BackStory, an American history podcast produced by ... Solitude in America .” , What is the history of solitude in America? ... does Thoreau’s solitary experiment at Walden Pond have to teach us all in the ...
(Date:1/20/2019)... ... January 18, 2019 , ... Dr. Faye Jamali, a ... of her state-of-the-art medical boutique, Belle Marin Aesthetic Medicine, with a grand opening ... wellness, guests will enjoy refreshments, prize drawings, and exclusive event-only pricing. Attendees will ...
(Date:1/20/2019)... ... January 19, 2019 , ... Bee Line Support, doesn't ... locations, certifying our management in the top infection prevention education , or ... stop at nothing to prove our unparalleled value. , This dedication to being ...
(Date:1/15/2019)... , ... January 15, 2019 , ... Ophthalmic Consultants of ... Stream office to a new, larger space at 70 East Sunrise Highway, Suite 400, ... the needs of its patients. , According to Gerard D’Aversa, MD, “After serving the ...
(Date:1/14/2019)... , ... January 14, 2019 , ... After many months ... a new clinic in Phoenix, Arcadia Allergy & Asthma. This new allergy and asthma ... making it a great one stop destination for any immunological and respiratory medical care ...
Breaking Medicine News(10 mins):